Key result
Levosimendan improves hemodynamics and symptoms in acutely decompensated heart failure, and is associated with lower mortality and morbidity compared to dobutamine or placebo.
Why the study?
Does levosimendan improve hemodynamics, symptoms, and outcomes in patients with decompensated heart failure compared to dobutamine or placebo?
Population
Patients with decompensated heart failure (both ischemic and non-ischemic etiology)
Comparison
Levosimendan (intravenous formulation) vs Dobutamine or placebo
Design
Review
Authors
Loading...
May support levosimendan in acute decompensated HF; leaves open confirmation of mortality benefit in large RCTs.
Does levosimendan improve hemodynamics, symptoms, and outcomes in patients with decompensated heart failure compared to dobutamine or placebo?
Levosimendan is an effective and potentially safer inodilator option for the treatment of acutely decompensated heart failure compared to traditional inotropes like dobutamine.
Kivikko et al. (2005) conducted a review in Decompensated heart failure. Levosimendan vs. Dobutamine or placebo was evaluated. Levosimendan improves hemodynamics and symptoms in acutely decompensated heart failure, and is associated with lower mortality and morbidity compared to dobutamine or placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: